Nov. 17, 2014
Acute lung injury (ALI) and its severe form, acute respiratory disease syndrome (ARDS), are life-threatening diseases with a variety of causes, including sepsis, trauma, and pneumonia. ALI and ARDS are characterized by pulmonary endothelial and epithelial injury, and loss of the alveolar capillary barrier with an influx of inflammatory cells. The incidence is estimated at 1.5 to 75 cases per 100,000 individuals and affects approximately 190,000 Americans annually, with mortality rates ranging from 25% to 40%. The current treatment approach to ALI/ARDS relies on ventilator and cardiovascular support. However, In spite of these treatments, unacceptable morbidity and mortality remain in ALI/ARDS patients. There is a great need for novel pharmacological therapeutics that can help reduce the morbidity and permanent lung tissue damage associated with ALI/ARDS.
Researchers at OSU have discovered a novel antibody that could constitute a new therapeutic method to restrict the pathogenesis of ALI/ARDS. In a clinically relevant animal model of ALI, a novel monoclonal antibody discovered by the researchers significantly inhibits neutrophil influx into alveolar space. Because neutrophil inflammation is central to development of ALI, this antibody may prove to be the therapeutic agent that is greatly needed for ALI/ARDS patients. Moreover, this anitibody could be used as a novel diagnostic marker for ALI/ARDS. This is critical because current diagnosis of ALI/ARDS is performed by the presence of non-cardiogenic pulmonary edema and respiratory failure, which are non-specific measures subject to inter-observer variability.
· Quantitative diagnostic tool for ALI/ARDS · Method of treatment for ALI/ARDS · Treatment for other inflammatory diseases, especially lung
· Enables early detection of ALI/ARDS · Novel treatment method to reduce severity of ALI/ARDS
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
non-specific measures subject
alveolar capillary barrier
mortality rates ranging
current treatment approach
non-cardiogenic pulmonary edema
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium